| Literature DB >> 31366029 |
Varvara A Mouchtouri1, Hannah C Lewis2, Christos Hadjichristodoulou3.
Abstract
A literature review was conducted to identify evidence of cases and outbreaks of vaccine-preventable diseases (VPDs) that have been reported from on board ships and the methods applied on board for prevention and control, worldwide, in 1990 to April 2019. Moreover, evidence from seroprevalence studies for the same diseases were also included. The literature review was conducted according to Preferred Reporting Items for Systematic reviews (PRISMA) guidelines. A total of 1795 cases (115 outbreaks, 7 case reports) were identified, the majority were among crew (1466/1795, 81.7%) and were varicella cases (1497, 83.4%). The origin of crew cases was from sub-tropical countries in many reports. Measles (40 cases, 69% among crew), rubella (47, 88.7%), herpes zoster (9, 69.2%) and varicella cases (1316, 87.9%) were more frequent among crew. Mumps cases were equal among passengers and crew (22/22). Hepatitis A (73/92, 70.3%), meningococcal meningitis (16/29, 44.8%), and pertussis (9/9) were more frequent among passengers. Two outbreaks resulted in 262 secondary measles cases on land. Review results were used to draft a new chapter for prevention and control of VPDs in the European Manual for Hygiene Standards and Communicable Disease Surveillance on Passenger Ships. Despite past and current evidence for cross-border VPD transmission and maritime occupational risks, documented pre-employment examination of immune status, vaccination of seafarers, and travel advice to passengers are not yet regulated.Entities:
Keywords: chickenpox; cruise; diphtheria; hepatitis A; maritime health; measles; meningococcal disease; mumps; occupational health; pertussis; rubella; sailors; seafarers; ship; travel; vaccination; vaccine; varicella
Mesh:
Year: 2019 PMID: 31366029 PMCID: PMC6696030 DOI: 10.3390/ijerph16152713
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1Flow chart of studies included in the review.
Descriptive analysis of outbreak and case reports of vaccine-preventable diseases.
| Disease | Dates, Number of Affected Voyages (Duration) | Diagnosis/Case Definition | No. Cases (Crew, Pax, Other) | Age, Sex, Nationality of Cases | No. Hospitalizations (HR), No. Deaths | Crew Attack Rate (of Susceptible) | Place of Occurrence/Ship Type | Vaccination/Infection History | Source/Risk Factor | Control Measures Described * | Reference |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
| 2 May–28 June 1996, 1 (2 months) | Rubella IgM+ or IgG+ plus clinical exanthema | 20 (20, 0, 0) | 18–33 years (mean 22.6); all male, | 0 (0%), 0 | 6% crew (57%) | Unkn. ‡. (ashore)/Military (German Navy ship) | A total of 9% ( | Crew; Hypothesized source: off ship pre-employment/Highest risk of infection: sleeping aboard ratings deck | A, C, E | [ |
| April–June 1997, multiple (3 months) | Rash illness | 7 (7, 0, 0) | Unkn., unkn. | 0 (0%), 0 | 0.8% crew (unkn) | Florida (USA) to Bahamas/Passenger (cruise) | Substantial proportion (96%, | Unkn. | B, I | [ | |
| 30 May–2 August 1997, multiple (2 months) | Rubella IgM+ or clinical Rubella plus epi-link to confirmed case | 16 (16, 0, 0) | Unkn., unkn. | 0 (0%), 0 | 4.2% crew (64%) | Florida (USA) to Bahamas/Passenger (cruise) | 75% of crew had negative or unknown vaccination history, | Unkn. | B, E, F, G, I | [ | |
|
| 2 February–18 July 2008, N/A (6 months) | Confirmed or epi-linked clinical measles | 155 (2, 1, 152) | Age range: 5 months-41 years (38% 20–29 years: 19% <2 years); 54% male, unkn. | 13 (8,4%),0 | N/A | Algeciras (Spain)—Tanger (Morocco)/Passenger (ferry) and Land (Algeciras and surrounds) | 72.1% of cases not previously vaccinated | Index cases were 2 crew and 1 passenger | A, F, G, N (vaccination and Ig to susceptible contacts) | [ |
| 19–26 Aug 2011, Various (8 days) | Confirmed measles | 5 (5, 0, 0) | Unkn., 4 male, 1 female, Philippines: 3, Honduras: 1, Italy: 1 | 0 (0%), 0 | 0.5% (unkn.) | Spain, Malta, Italy/Passenger | Unkn. | Unkn. | A, B, C, D, E, F, G, H, I, J | [ | |
| 8 February–July 2014, N/A (6 months) | Epi-linked and confirmed | 80 (0, 1, 79) | Median age 26 years (range: 8 months–55 years); 50 (62.5%) female, N/A | 35/78 (44.9%), 0 | Unkn. | Sardinia, Italy/Land | 74/76 cases (97.4%) unvaccinated: 2 (2.6%) with one dose of measles vaccine | Cruise ship passenger | H, G, N (all susceptible staff invited for vaccination) | [ | |
| 20 February–10 March 2014, | Clinical, epi- linked and confirmed | 29 (23, 6, 0) | 1–42 years (median 26); 21/27 (78%) male, Asia (71%), Europe (21%), S. America and Caribbean (7%), Africa (0.5%) Median age 19 years (range: 0–39 years); 17 (53%) female, | 10/27 (37%), 0 | 2.4% (unkn.) | Mediterranean Sea (Italy, France, Spain)/Passenger (cruise) | Vaccination status of 24 cases: unkn. ( | Index case: crew member(s): infected during cruise, possibly at one of stops | A, B, E, F, G, H, I, J, K, O | [ | |
| 27 February–May 2014, N/A | Clinical, epi- linked and confirmed | 32 (0, 1, 31) | Unkn. | Unkn. | Unkn. | Brindisi province, Puglia Region, Italy/Land | Unknown; 1/32 cases vaccinated with one dose of MMR | Cruise ship passenger | H, N (MMR vaccination for 2 cases on land as PEP and of close contacts) | [ | |
|
| 1998, unkn. (unkn.) | Clinical varicella case | 3 (3, 0, 0) | Unkn., | Unkn. | <1% (unkn.) | New York Harbor/Passenger (cruise) | Susceptibility rate including infected 13%. | Unkn. | A, C, I | [ |
| 28 January–15 April 2006 Multiple (7 days), (11 weeks) | Rash illness | 16 (16, 0, 0) | Index cases 23 and 35 years, unkn., Ukraine and Philippines. | 0 (0%), 0 | 1.3% (unkn.) | Florida (US) to Caribbean./Passenger (cruise) | Three crew members (<1%) had proof of immunity (vaccine record) to measles and rubella | All index cases were crew members; close crew interactions outside of work as risk factor | A, B, E, F, G, H, I | [ | |
| February–November 2008 5 ships (unkn.), (10 months) | Clinical varicella case | 28 (28, 0, 0) | Unkn., | 0 (0%), 0 | Unkn. | Mediterranean Sea/Passenger | Unkn. | Unkn. | I | [ | |
| 20 February–30 March 2012, 1 (5 weeks) | Clinical varicella case | 3 (2, 1, 0) | 4 years, male, unkn. | 0 (0%), 0 | <1% (unkn.) | UK, Spain, Portugal/Passenger | Unkn. | Unkn. | A, B, C, D, E, G, I | [ | |
| 29 September–2 October 2014, 1 (4 days) | Clinical varicella case | 1 (1, 0, 0) | 27 years, male, unkn. | 0 (0%), 0 | Unkn. | Malta, Spain/Passenger | Unkn. | Unkn. | A, B, C, D, E, G, I | [ | |
| 16 January–20 February 2015 Various (5 weeks) | Clinical varicella case | 5 (5, 0, 0) | 34 years, male, unkn., Indonesia | 0 (0%), 0 | Unkn. | Spain, Italy/Passenger | Unkn. | Unkn. | A, B, C, D, E, G, I | [ | |
| 26–30 December 2015, N/A (1 week) | Varicella pneumonia | 1 (1, 0, 0) | 50 years, male, Indian | 1/1 (100%), 1 (cause of death varicella pneumonia) | 1/24 (unkn.) | Puerto Rico/Cargo | Unkn. | Unkn. | A, B, E, I | [ | |
| 12–21 September 2016 | 5 (5, 0, 0) | Unkn. | 0 (0%), 0 | Unkn. | Belgium/Cargo ship | Unkn. | New crew members from the Philippines arrived (22/08/2016) prior to the outbreak or by contacting people in the port | A, B, C, E, I | [ | ||
| February 2018, 1 | Clinically diagnosed varicella | 1 (1, 0, 0) | Unkn., male, Philippines | 0 (0%), 0 | Unkn. | Spain/Container ship | Unkn. | Unkn. | A, B, I, E | [ | |
|
| 1 September–30 November/2008, 3 (3 months) | Clinically compatible case with IgM anti-HAV, disease onset 1 Sept–30 Nov and travel history to Egypt 2–6 weeks prior to symptom onset | 10 (0, 10, 0) | Median 41 years (range 23–59); male to female ratio 3:7, N/A | 1 (10%), 0 | Unkn. | Nile river, Belgium/Passenger (river cruise | No case vaccinated against hepatitis A | Continuing common source, most likely linked to river cruise | B | [ |
| September–November 2008, 6 (5–14 days), (10 weeks) | Hepatitis A cases (symptoms + lab confirmation of acute infection) with onset from 1 Sept 2008 and travel to Egypt 15–50 days prior to symptom onset | 34 (0, 34, 0) | Mean age 40.1 years (range 11–69); 59% female, N/A | 20 (59%), 0 | Unkn. | Nile river, Germany/Passenger (river cruise | No case vaccinated against hepatitis A | Continuing common source, most likely linked to river cruise | B | [ | |
| 13 September–28 October 2009, 5 (9 weeks) | Person with IgM anti-HAV who had stayed in Egypt 2–6 weeks prior to symptom onset | 26 (0, 26, 0) | Mean age 32.8 years (range 10–65); 50% female, N/A | 17 (65%), 0 | Unkn. | Nile river, France/Passenger (river cruise | No case vaccinated against hepatitis A | Continuing common source, most likely linked to river cruise | B | [ | |
| January 2011, 1 (unkn.) | Subgenotype IB imported case | 1 (1, 0, 0) | 28 years, male, Polish | 0, 0 | Unkn. | Argentina (USA–South American Pacific–Atlantic Coast)/Passenger (river cruise | Self-report of one dose hepatitis A vaccine in previous year | Crew index case; Possible risk factor: consumption of shellfish on land in Mexico | O | [ | |
|
| 15 June–13 August 1992, 1 (unkn.) (2 months) | Clinical mumps | 9 (9, 0, 0) | Mean 24 years (Range: 18–35); unkn., unkn. | 2 (22%), 0 | 4% (unkn.) | Western Pacific, route: Japan to Hawaii (US)/Military (“US Reuben James” Navy ship) | Three cases had mumps or MMR vaccine documented | Unkn. | O | [ |
|
| 1997, | Confirmed | 1 (0, 1, 0) | 72 years, female, unkn. | 1 (100%), 0 | N/A | Baltic sea/Passenger (cruise) | Unkn. | Travelling in former USSR/Baltic | C, N (Diptheria antitoxin and antibiotics to case and close family, contacts received antibiotic prophylaxis and low dose diphtheria vaccine boosters) | [ |
|
| May 2003, | Clinical meningococcal meningitis | 1 (1, 0, 0) | 24 years, male, unkn. | 0, 0 | Unkn. | Mid Atlantic ocean/Military (aircraft carrier) | Patient had received meningococcal vaccine three years previously. | Unkn. | A, C, H, N (Chemoprophylaxis to close contacts from the ship) | [ |
| October 2012, 1 (unkn.), (<1 month) | Confirmed | 4 (4, 0, 0) | Unkn., unkn., originated from three different continents | 4 (100%), 1 (25%) | Unkn. | Italian coast/Passenger (cruise) | Unkn. | All cases worked in ship kitchen | B, N (Chemoprophylaxis to all passengers and crew on ship) | [ | |
| October 2017, 1 | Clinical meningitis | 1 (1, 0, 0) | Unkn., female, unkn. | 1, unkn. | Unkn. | Greece/Passenger (cruise) | Unkn. | Unkn. | A, B, D, I, O | [ |
HR: Hospitalization rate; CFR: Case fatality rate; * Control measures: A = isolation, B = report to competent authority, C = treatment, D = cleaning/disinfection, E = case finding/active surveillance in crew, F = case finding/active surveillance in passengers or others, G = risk communication, H = contact tracing, I = crew vaccination, J = passenger vaccination, K = quarantine, L = immunoglobulin (Ig) for crew, M = immunoglobulin (Ig) for passengers, N = other post-exposure prophylaxis (PEP) (describe details), O = disembarkation. ‡ Unkn. = unknown
Vaccine-preventable diseases identified through record review studies.
| Disease | Dates (Number of Affected Voyages, Duration) | Diagnosis/Case Definition | No. Cases (Crew, Passenger, Other) | Age (Years), Sex, Nationality of Cases | Population at Risk/Crew Attack Rate (of Susceptible) | Place of Occurrence/Ship Type | Control Measures Described * | Reference |
|---|---|---|---|---|---|---|---|---|
|
| 2005–2009 (unkn., 5 years) | Clinical varicella case | 357 (278, 0, 79) | Crew: Median age 29 (range 20–66), 80% male | 2305 maritime illness reports | Sailing in US waters/passenger | A, B, C, E, F, G, H, I, J | [ |
| November 2007–April 2008 (4 ships, 6 months) | Clinical varicella case | 5 (5, 0, 0) | 26–42 years, male | 13, 377, 28, and 882 crew, respectively | Baltic sea/Europe/Med/USA and Caribbean/passenger (2) cargo (1) work (feeder) ship (1) | A, B, C, E, F, G, H, I, J (instructed but unclear what was carried out) | [ | |
| 2009–2010, 34 ships (2–25 days, 2 years) | Clinical varicella case (probable case) | 187 (151, 36, 0) | Unkn. >130 countries. 26 countries for crew cases with 58% from 5 sub-tropical or tropical countries (the Philippines, Indonesia, India, Jamaica, St. Vincent and the Grenadines) | 694–6300 passengers per ship; | World-wide/passenger | A, B, C, E, F, G, H, I, J | [ | |
| January 2010–December 2015, 99 outbreaks | Diagnosis of authority’s medical officer | 967 (823 including 758 cruise ship crew, 144, 0) | Crew: 20–49: 394/399, 50+: 5/399, | Unknown | USA/63 cargo ships, 900 cruise ships | A, B, C, H, I, J, O | [ | |
|
| January 2010–December 2015 | Diagnosis of authority’s medical officer | 13 (9 including 7 cruise ship crew, 4, 0) | Unkn. | Unkn. | USA/2 cargo ships, 11 cruise ships | Unkn. | [ |
|
| January 2010–December 2014 | Presumptive or final diagnoses based on the information available from healthcare facilities, health departments, medical examiners, or laboratories, when available, and review by a quarantine medical officer | 35 (13, 22, 0) | Unkn. | Unkn. | Unkn. | Unkn. | [ |
|
| January 2010–December 2014 | Presumptive or final diagnoses based on the information available from healthcare facilities, health departments, medical examiners, or laboratories, when available, and review by a quarantine medical officer | 25 (9, 16, 0) | Unkn. | Unkn. | Unkn. | Unkn. | [ |
|
| January 2010–December 2014 | Presumptive or final diagnoses based on the information available from healthcare facilities, health departments, medical examiners, or laboratories, when available, and review by a quarantine medical officer | 22 (19, 3, 0) | Unkn. | Unkn. | Unkn. | Unkn. | [ |
|
| January 2010–December 2014 | Any probable or confirmed measles case determined to be contagious during travel. Presumptive or final diagnoses based on the information available from healthcare facilities, health departments, medical examiners, or laboratories, when available, and review by a quarantine medical officer | 21 (10, 11) | Unkn. | Unkn. | Unkn. | Unkn. | [ |
|
| January 2010–December 2014 | Presumptive or final diagnoses based on the information available from healthcare facilities, health departments, medical examiners, or laboratories, when available, and review by a quarantine medical officer | 10 (4, 6) | Unkn. | Unkn. | Unkn. | Unkn. | [ |
|
| January 2010–December 2014 | Presumptive or final diagnoses based on the information available from healthcare facilities, health departments, medical examiners, or laboratories, when available, and review by a quarantine medical officer | 9 (0, 9) | Unkn. | Unkn. | Unkn. | Unkn. | [ |
Seroprevalence studies.
| Disease, Study Duration [Reference] | Study Date (Duration) | Study Sample | Serological Markers * | No. Study Subjects (Age, Sex, Nationality | Seropositivity | Seropositivity By Age | Seropositivity by Nationality | Susceptibility | Vaccination/Infection History | Risk Factors |
|---|---|---|---|---|---|---|---|---|---|---|
| 1989–1991 | US military personnel scheduled for deployment on 11 US Navy ships | Anti-HAV+, | 2072 (male, mean 24 years; 72% white) | Anti-HAV+ | Increasing with age: HAV+ 7.8% in 18–24 years; 28.7% in >34 years | For country of birth: | HAV: 90% | 28 subjects reported a history of acute hepatitis (50% were anti HAV+ compared to 9.6% without a history) | Anti-HAV positivity associated with age, non-white racial/ethnic group, born outside US and prior Caribbean deployment for <1 year. Anti-HBV with black and Philippino race, foreign birth, a history of STD and South Pacific/Indian Ocean deployment for <12 months, and S Pacific or Med duty for >1 year | |
| April–December 1993 (9 months) | Seamen attending five clinics performing mandatory health examinations of seamen in Denmark | Anti-HAV+, Anti-HBc+, | 515 (86% male; 94% Scandinavian) | Anti-HAV+ | Increasing with age: HAV+ 0.3% in <40; 71% in 60–69 years. | For origin: Anti-HAV+ 12.8% for Scandinavian and 52.4% for foreign; | HAV: 85% | 1 HAV+ case previously had HAV vaccination | Anti-HAV and HBV positivity associated with age. HAV seroprevalence highest among those who sailed in international trade (outside USA and Europe) | |
| February–July 1998 | Personnel from a Greek warship | Anti-HAV+, Anti-HBsAg+ | 263; (male, mean age 24.4 years) | Anti-HAV+ | Unkn. | Unkn. | HAV: 100% | 23 subjects reported vaccination against Hepatitis B (three doses by 14 subjects) | Unkn. | |
| 1–23 December 2008 (3 weeks) | Cruise ship crew members undergoing pre-employment medical exam in Mumbai and Goa | VZV IgM+ and IgG + | 121 (male, 21–42 years, 100% Indian) | 100 (82.7%) IgG+ | Unkn. | Unkn. | 16.5% susceptibility | 60% IgG pos. crew could remember disease or vaccine history | Unkn. |
* anti-HAV: antibodies to hepatitis A virus, anti-HBc: antibodies to hepatitis B core antigen, anti-HCV: antibodies to hepatitis C virus, Anti-HBsAg: antibodies to hepatitis B surface antigen, VZV: Varicella Zoster Virus, IgM: immunoglobulin M, IgG: immunoglobulin G, Unkn.: unknown, STD: Sexually Transmitted Disease.
Characteristics of cases from reported outbreaks, case reports, and record reviews (results from seroprevalence studies not included).
| Disease | No. Clusters/Outbreaks > 1 Cases | No. Crew Cases | No. Pax Cases | Total Crew, Pax/Total Cases | No. Other Cases | Male/Female | Origin of Cases | Ship Type | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Out. Rep. ‡ | Rev.Rec. ∞ | Out. Rep. | Rev. Rec | |||||||
| Measles | 3 | 30 | 10 | 7 | 11 | 40, 18/58 (3, 2) | 262 * | 25/7 | Asia, Europe, S. America, Caribbean, Africa, Italy, India, Philippines, Honduras, Austria, Brazil, Indonesia, unkn. | 1 ferry, 2 cruise |
| Rubella | 3 | 43 | 4 | - | 6 | 47, 6/53 (3, 0) | 0 | 20/- | German, unkn. | 2 cruise, 1 military |
| Hepatitis A | 3 | - | 19 | 70 | 3 | 19, 73/92 (5, 1) | 0 | 31/40 | Polish, unkn. | 4 river cruise ships |
| Meningococcal meningitis | 1 | 4 | 9 | - | 16 | 13, 16/ 29 (1, 6) | 0 | 1/1 | unkn. | 2 cruise, 1 military |
| Mumps | 1 | 9 | 13 | - | 22 | 22, 22/44 (2, 5) | 0 | -/- | unkn. | 1 military |
| Pertussis | unkn √. | - | - | - | 9 | 0, 9/9 (0, 5) | 0 | -/- | unkn. | - |
| Herpes zoster | unkn. | - | 9 | - | 4 | 9, 4/13 (0, 7) | 0 | -/- | unkn. | 11 cruise, 2 cargo |
| Varicella | 104 | 59 | 1257 | 1 | 180 | 1316, 181/1497 (83, 4) | 79 † | 687/130 | Indonesia, India, Philippines, SE Asia, Eastern European countries, Sri Lanka, Caribbean countries, unkn. | 909 cruise, 69 cargo |
|
|
|
|
|
|
|
|
|
|
| |
* For example, secondary cases on land, † either passenger cases or their contacts, ‡ Outbreak Report (Out.Rep.), ∞ Review Record (Rev.Rec.), √ Unknown (unkn.).